Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC9528 | C75 (trans) Featured | C75 trans is the trans form of C75; C75 is a potent fatty-acid synthase(FASN) inhibitor with IC50 of 35.4 μM(LNCaP cell Proliferation inhibition). |
![]() |
DC43980 | FASN-IN-3 | FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A. |
![]() |
DC70453 | GSK2194069 | GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of human fatty acid synthase (hFAS) with IC50 of 7.7 nM (CoA release); shows an IC50 of 29 nM versus hFAS with acetoacetyl-CoA as the substrate, but shows little or no inhibition with β-hydroxybutyrylCoA and crotonyl-CoA (IC50 >1,000 nM), also does not inhibit the partial activities of the KS domain; decreases phosphatidylcholine levels in A549 cells with IC50 of 15.5 nM without effect on FAS protein levels, reduced A549 cell growth with EC50 of 15 nM. |
![]() |
DC73734 | Fasnall benzenesulfonate | Fasnall benzenesulfonate is a potent, selective fatty acid synthase (FASN) inhibitor with IC50 of 3.71 uM for purified human FASN isolated from the BT474 cell line. |
![]() |
DC73735 | FASstatin | FASstatin (FASNi-8) is an orally bioavailable small-molecule inhibitor of fatty acid synthase (FASN), directly binds FASN with SPR KD of 16 uM, potentiates TRIM56-mediated FASN ubiquitination. |
![]() |
DC73736 | NJNU-0069 | NJNU-0069 is a specific small-molecule inducer of major histocompatibility complex class II (MHC-II), directly binds to the MAT domain of FASN (Kd=32.1 uM). |
![]() |
DC73737 | NJNU-0069-003 | NJNU-0069-003 is a specific small-molecule inducer of major histocompatibility complex class II (MHC-II), directly binds to the MAT domain of FASN with Kd of 7.98 uM. |
![]() |